SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

EP: 1.Coming Soon: THE TALK: Breast Cancer, A Review of Data from the SABCS 2021 Virtual Meeting

EP: 2.SABCS 2021 Updates in ER+ Breast Cancer

EP: 3.SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

Now Viewing

EP: 4.SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

Data from the following clinical trials are discussed:

• GS2-05 oral presentation: Randomized comparision of adjuvant aromatase inhibitor exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS in premenopausal women with hormone receptor-positive early breast cancer: update of the TEXT and SOFT trials
• GS3-00: First results from a phase 3 randomized clinical trail of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score < 25: SWOG S1007 (RxPONDER)
• GS1-08: CCTGMA.32, a phase 3 randomized double-blind placebo-controlled adjuvant trial of metformin vs placebo in early breast cancer: Results of the primary efficacy analysis (NCT0110143)
• GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2 breast cancer: Results from the phase 1 TROPION-PanTumor01 study